Clinical-grade purification and expansion of CD56⁺CD3⁻ NK cells for adoptive immunotherapy of solid tumors and leukemia

Ulrike Koehl¹, Ruth Esser¹, Lutz Uharek², Martin Stern³, and Jakob Passweg¹

¹ Institute of Cellular Therapeutics GMP Development Unit (OE 8885), IFB-Tx and Cellular Therapy Centre Hannover Medical School (MHH), Hannover, Germany
² Internal Medicine, Hematology and Oncology, Charité Berlin, Germany.
³ Division of Hematology, University Hospital Basel, Switzerland.
Clinical-grade purification and expansion of CD56+CD3− NK cells for adoptive immunotherapy of solid tumors and leukemia

Ulrike Koehl1, Ruth Esser1, Lutz Uharek2, Martin Stern3, and Jakob Passweg3

1 Institute of Cellular Therapeutics GMP Development Unit (OE 8885), IFB-Tx and Cellular Therapy Centre Hannover Medical School (MHH), Hannover, Germany
2 Internal Medicine, Hematology and Oncology, Charité Berlin, Germany.
3 Division of Hematology, University Hospital Basel, Switzerland.

Introduction

Cell therapy may represent a promising treatment option for patients who suffer from leukemia and tumors and have a high risk for relapse after allogeneic, especially haploidentical, stem cell transplantation (SCT). While established T cell therapies, such as donor lymphocyte infusions, are associated with the risk of graft-versus-host disease (GvHD), natural killer (NK) cells may mediate graft-versus-leukemia/tumor effects without induction of GvHD. Therefore, immunotherapy with highly purified NK cells in recipients of haploidentical SCT could serve as an attractive alternative cell therapy¹, ².

Human NK cells are lymphocytes of the innate immune system involved in the early defense against infectious pathogens and against MHC class-I–negative or –low-expressing malignant targets without the requirement for prior immune sensitization of the host³, ⁴. They reside mainly in the marrow, spleen, and peripheral blood, where they account for approximately 2–18% of the peripheral blood lymphocytes. NK cells are usually the first lymphoid subpopulation to recover after SCT⁵. Phenotypically they can be defined by the expression of CD56, an isoform of the neural cell adhesion molecule and the lack of the CD3 antigen on the surface. Further characterization allows the major CD56dimCD16+ (around 90%) to be distinguished from the minor CD56brightCD16− NK subpopulation. The immunoregulatory CD56bright NK cell subsets express the high-affinity interleukin 2 (IL-2) receptor, which enables them to proliferate in response to IL-2 and to produce high amounts of cytokines, such as IFN-γ, TNF-α, TNF-β, GM-CSF, IL-10, and IL-13. The CD56dim NK cells are essentially cytotoxic cells that express low levels of the IL-2 receptor. NK cells are able to lyse targets by releasing cytotoxic granules containing perforin and granzymes and using antibody-dependent cellular cytotoxicity pathways via membrane receptor binding to the Fc portion of IgG antibody, and by the induction of apoptosis through molecules of the TNF superfamily (Fas/CD95, TRAIL). Killing activity of NK cells is regulated by a set of surface receptors that either induce or inhibit the cytotoxic response⁶, ⁷. Activation of NK cells is facilitated by the engagement of activating surface receptors through interaction with stimulatory ligands expressed by malignant cells. These immune recognition receptors include NKG2D, the natural cytotoxicity receptors (NCR) Nkp30, Nkp44, and Nkp46, CD16, Nkp80, DNAM-1, and 2B4 (CD244)⁸. Activation with cytokines, such as IL-2, leads to a strong up-regulation of the NCRs and NKG2D, and this correlates with increased NK cell cytotoxicity against malignant cells⁹. Inhibitory receptors comprise both killer cell immunoglobulin-like receptors (KIRs) and the heterodimeric C-type lectine receptor CD94-NKG2A/B⁹. In addition, several activating KIR and the C-type lectin receptor CD94-NKG2C/E/F are known. A number of studies have demonstrated NK cell–based killing of many different mouse and human tumors and leukemias and have led to the initiation of the first clinical phase I/II trials using allogeneic NK cells for treatment of cancer.

Materials and methods

Clinical-scale NK cell enrichment

Protocols for the enrichment of NK cells from non-stimulated leukapheresis products using good manufacturing practice (GMP) procedures have already been established (table 1; fig. 1). The aim of these procedures is to obtain a highly purified NK cell product with minimal T cell contamination and conserved...
Clinical phase I/II study with allogeneic NK cells post haploidentical SCT: Patients with high-risk leukemia and malignant tumors

**Leukapheresis**

Donor/Parents

**NK cell purification**

CD3⁺ depletion followed by CD56⁺ cell enrichment, according to GMP

**NK cell expansion**

IL-2–dependent, according to GMP

**NK cell infusion**

Recipient

<table>
<thead>
<tr>
<th>haploidentical SCT</th>
<th>NK cell infusion</th>
<th>NK cell infusion</th>
<th>NK cell infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>+3</td>
<td>+40</td>
<td>+100</td>
</tr>
</tbody>
</table>

**Figure 1** Purification, ex vivo expansion, and infusion of donor NK cells. In an ongoing clinical phase I/II trial patients receive freshly isolated NK cells on day +3, +40, +100 or IL-2–activated NK cells on day +40 and +100 post haploidentical SCT.

NK cell cytotoxicity. NK cell enrichment usually consists of one or two rounds of CD3⁺ cell depletion with subsequent CD56⁺ cell enrichment¹¹⁻¹³.

In our procedure, after steady-state leukapheresis of unstimulated donors, the cells were washed twice for platelet reduction with CliniMACS® PBS/EDTA Buffer (Miltenyi Biotec, Bergisch Gladbach, Germany) supplemented with 0.4% human serum albumin (Red Cross Blood Donor Service, Baden-Württemberg-Hessen, Germany). Thereafter, 5 mL of Intraglobin (Biotest, Dreieich, Germany) were added and incubated for five minutes to reduce non-specific antibody binding. Cells were labeled for 30 minutes with CliniMACS CD3 Reagent (Miltenyi Biotec), using one vial of reagent in case of total nucleated cell (TNC) numbers up to 40×10⁹ or CD3⁺ cell numbers up to 15×10⁹ and two vials in case of TNC numbers up to 80×10⁹ or CD3⁺ cell numbers up to 30×10⁹. After washing twice, CD3⁺ cells were depleted with the CliniMACS Plus Instrument using the separation program “DEPLETION 2.1”. If necessary, the T⁺ cell depletion step was repeated to further remove residual T⁺ cells. Thereafter, the T⁺ cell–depleted harvests were concentrated and labeled with CliniMACS CD56 Reagent (Miltenyi Biotec) for 30 minutes (one vial CD56 Reagent for TNC numbers up to 40×10⁹ and CD56⁺ cell numbers up to 10×10⁹). After washing, CD56⁺CD3⁻ NK cells were enriched using the separation program "ENRICHMENT 1.1". All steps were performed in a closed system observing GMP. The study protocol was approved by the local ethics committee in Frankfurt and Basel and informed consent of the donors has been obtained.

**Expansion and activation of NK cells**

The purified CD56⁺CD3⁻ NK cells were suspended and seeded at a concentration of 1–2×10⁶ cells/mL in X-VIVO™ 10 media (BioWhittaker, Verviers, Belgium) supplemented with 5% heat-inactivated human fresh frozen plasma and 1,000 U/mL rhIL-2 (Proleukin®, Novartis, Germany) under GMP-compliant conditions (fig. 1). In an early phase of the study, cells had been expanded and activated using both 175 cm² culture flasks (Nunc, Wiesbaden, Germany) and VueLife™ cell culture bags (CellGenix, Freiburg, Germany); for the ongoing phase I/II trial only VueLife cell culture bags were used¹¹. Fresh medium was added every three days, and samples for monitoring cell content and viability were taken directly after leukapheresis, after each depletion/enrichment step, and every second day during stimulation. Phenotyping and evaluation for cytotoxicity was performed by flow cytometry. After 10 days, stimulated NK cells were administered to the patients or cryopreserved in X-VIVO 10 medium supplemented with 10% DMSO.

**Phenotyping and functional characterization of the product for quality control**

The absolute number of CD56⁺CD3⁻ NK cells and the number of residual T⁺ cells were determined by flow cytometry performed on a four- or a five-color flow cytometer (Epics XL or FC 500, Beckman Coulter, Krefeld, Germany) in a single-platform technique. The gating strategy was based on the ISHAGE single-platform stem cell enumeration method using low scatter, high expression of CD3 and CD45 antigens, CD16 and CD56 expression and 7-AAD staining, in a no-wash preparation with counting beads. Our previously described four-color panels¹⁴ were extended to the following five-color panels: CD45-FITC/CD56-PE/CD3-ECD/7-AAD/CD16-PC7 and CD45-PE/CD3-APC/CD56-PE/7-AAD/CD16-PC7.

**Figure 1** Purification, ex vivo expansion, and infusion of donor NK cells.
CD45-FITC/CD3-PE/CD14-ECD/7-AAD/CD56-PC7. Samples were prepared in triplicate and CD45-FITC/IgG1-PE/CD14-ECD/7-AAD/CD56-PC7 served as a control. In addition, cells were labeled with appropriate combinations of fluorochrome-conjugated antibodies (MAb) to monitor NK cell subsets, activating and inhibitory NK cell receptors, and activation status. MAbs used were CD16 (clone 3G8), CD45 (clone J33), CD56 (clone N901), HLA-DR (clone Immu-357), CD69 (clone TP1.55.3), CD158a/h (KIR2DL1/S1, clone EB6B), CD158b1/b2,j (KIR2DL2/3/S2, clone GL183), CD158e1/e2 (KIR70, KIR3DL1/S1, clone Z27.3.7), CD158i (KIRp70, KIR3DL1/S1, clone Z231), CD335 (NKp46, clone BAB281), and CD314 (NKG2D, clone ON72), all supplied by Beckman Coulter (Marseille, France), and CD3 (clone SK7) supplied by BD* Biosciences.

The cytotoxicity of the highly enriched NK cells was determined using Flow-Count™ beads. A number of studies have shown that clinical-grade NK cell enrichment using the CliniMACS® System allows the infusion of NK cell products of more than 1.0×10⁶ CD56+CD3- NK cells/kg BW with less than 5.0×10⁵ CD3+ cells/kg BW and often less than 2.5×10⁵ CD3+ T cells/kg BW. The objective of NK cell purification is not only to remove potentially unwanted T cells but also to enable activation and expansion of the NK cells. Indeed, enriched NK cells can be infused without any additional manipulation, or after overnight culture in high-dose IL-2. They can also be expanded in IL-2 or other cytokines, such as IL-15, alone or in combination, for two to several weeks in cell culture bags or in a bioreactor. Similarly, it is possible to expand single KIR+ NK cells. In vitro expansion has two aims, to activate the selected CD56+CD3- cells, and to increase the total number of NK cells. Using CD69 as an activation marker, activation of NK cells was found to occur within 1–3 days of incubation with IL-2. When enriched CD56+CD3- NK cells were cultured with IL-2, a significant expansion was observed although there was a lag of 3–5 days before the NK cells started to proliferate. On day 5, expansion occurred and led to a 2- to 10-fold increase of CD56+CD3- NK cells after 10–14 days. Although NK cells were viable immediately after purification (>90%), the vital NK cell count decreased by 30–50% during the first three to five days following IL-2 stimulation. Afterwards, cell viability recovered to >98%, and by day 10–14, a maximal NK cell expansion was obtained. No overgrowth of the remaining T cells was observed during expansion and activation.

In Table 1, a comparison of various NK cell enrichment methods and their efficiency is presented. The table shows the NK cell purity, recovery, and log T cell depletion for each method. The purity and recovery values range from low to high, with some methods achieving nearly 100% recovery, while others have lower recoveries. The log T cell depletion values indicate the degree of T cell depletion, with lower values indicating more efficient T cell depletion.

### Table 1: Clinical-grade NK cell enrichment using the CliniMACS® System.

<table>
<thead>
<tr>
<th>Author</th>
<th>Method</th>
<th>Donors (n)</th>
<th>NK cell purity (%)</th>
<th>Recovery (%)</th>
<th>Log T cell depletion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lang et al. (2002)</td>
<td>CD56 enrichment, followed by CD3 depletion</td>
<td>4</td>
<td>98.6 (m)</td>
<td>42.0 (m)</td>
<td>3.6×10⁴-fold</td>
</tr>
<tr>
<td>McKenna et al. (2007)</td>
<td>CD3 depletion</td>
<td>36</td>
<td>37.7 (x)</td>
<td>78.8</td>
<td>2.7</td>
</tr>
<tr>
<td>McKenna et al. (2007)</td>
<td>CD3 depletion, followed by CD56 enrichment</td>
<td>13</td>
<td>89.7 (x)</td>
<td>19.4</td>
<td>4.3</td>
</tr>
<tr>
<td>Koehl et al. (2004)</td>
<td>CD3 depletion, followed by CD56 enrichment</td>
<td>6</td>
<td>95.0 (m)</td>
<td>37.0 (m)</td>
<td>4.5 (m)</td>
</tr>
<tr>
<td>Koehl et al. (2005)</td>
<td>CD3 depletion twice, followed by CD56 enrichment</td>
<td>15</td>
<td>94.9 (m)</td>
<td>33.0 (m)</td>
<td>5.0 (m)</td>
</tr>
<tr>
<td>Iyengar et al. (2003)</td>
<td>CD3 depletion, followed by CD56 enrichment</td>
<td>12</td>
<td>91.0 (m)</td>
<td>48.7 (m)</td>
<td>5.3 (m)</td>
</tr>
<tr>
<td>Uharek et al. (2003)</td>
<td>CD34 neg fraction: CD3 depletion, CD56 enrichment</td>
<td>7</td>
<td>75.0 (m)</td>
<td>42.0 (m)</td>
<td>4.0</td>
</tr>
<tr>
<td>Passweg et al. (2004)</td>
<td>CD3 depletion, followed by CD56 enrichment</td>
<td>6</td>
<td>97.3 (m)</td>
<td>35.5 (m)</td>
<td>3.6</td>
</tr>
<tr>
<td>Meyer-Monard et al. (2009)</td>
<td>CD3 depletion, followed by CD56 enrichment</td>
<td>24</td>
<td>94.5 (m)</td>
<td>58.0 (m)</td>
<td>4.2 (m)</td>
</tr>
<tr>
<td>Rizzieri et al. (2010)</td>
<td>CD56 enrichment</td>
<td>51</td>
<td>96.5</td>
<td>80</td>
<td></td>
</tr>
</tbody>
</table>

m: median; x: mean

Vol 15 • 2/2013
with IL-2. With a protocol that enables the generation of NK cells on a clinical scale, using a closed system that conforms to GMP guidelines, the expanded NK cells were highly cytotoxic against different leukemic and tumor target cells. Importantly, no non-specific activation against normal allogeneic lymphocytes occurred. In addition we were able to demonstrate that IL-2 stimulation led to up-regulation of all natural cytotoxicity receptors (NCRs) and the activating receptor NKG2D, which might explain the observed increased cytotoxicity against MHC-I-negative targets. There is evidence that a combination of cytokines, such as IL-2, IL-12, IL-15, and IL-21, may further increase cytotoxic activity of NK cells. In addition to NK cell enrichment from leukapheresis products as summarized in Table 1, NK cells can also be generated from cord blood.

Clinical-scale collection, enrichment, activation, and expansion of purified NK cells are feasible. Most of the technical aspects for adoptive NK cell therapy have been developed for clinical applications. However, these laboratory procedures are time consuming and expensive, need particular skills, and must be performed according to a GMP-compliant protocol.

Clinical studies using freshly purified or IL-2-activated NK cells

Previous trials and ongoing clinical phase I/II studies have shown the feasibility of using freshly purified or IL-2-activated donor NK cells for the treatment of high-risk patients suffering from leukemia or tumors in both non-transplant settings and after haploidentical SCT as an additional immunotherapy. NK cell products were infused as a single dose rate or as multiple applications with doses between 0.2×10⁷ and 8.1×10⁷ CD56⁻CD3⁻ NK cells/kg BW, mostly with less than 2.5×10⁶ CD3+ T cells/kg BW. These first immunotherapy trials show that NK cells can be administered without immediate adverse events, that they are well tolerated by the patients and do not induce GvHD > grade II. However, some cases of GvHD have been observed after NK cell infusion. In some instances this has been associated with a less efficient T cell depletion. Whether GvHD is attributable to contamination by T cells or is due to the effects of NK cells cannot be determined on the basis of this clinical data. The fact that (at least in some cases of GvHD) the T cell content was higher than in cases without GvHD, seems to favor a T cell effect. With regard to NK cell efficiency, Rubnitz et al. recently reported that NK cell administration to ten pediatric patients with AML in first complete remission led to a two-year event-free survival of 100%, with all patients still in complete remission. An earlier study demonstrated that patients with AML had a lower rate of leukemia relapse compared to the expected rate, a lower rate of graft rejection, and a paradoxical reduction in GvHD post-haploidentical SCT, when the NK cells possessed inhibitory KIRs for which the recipient had no ligand. We could show an increased cytotoxic activity of stimulated NK cells against high-risk neuroblastoma (NB) due to IL-2-mediated up-regulation of the activating receptors Nkp30, Nkp44, Nkp46, and NKG2D. However, we have also been able to demonstrate tumor escape from immune surveillance by release of soluble MICA (ligand MHC class I-chain-related gene A) compromising NKG2D-dependent NK cell cytotoxicity in patients with NB. Elevated sMICA levels in patients’ plasma correlated significantly with impaired NK cell-mediated cytotoxicity of the infused donor NK cells.

Future perspectives

Future studies should improve NK cell immunotherapy by increasing the understanding of the conditions leading to tumor cell kill by NK cells, by increasing the cytotoxicity of NK cells against various malignancies, and by optimizing the schedule of the NK administration based on results of ongoing phase I/II studies. Given the plausible benefit of IL-2-stimulated NK cells compared to freshly isolated, resting NK cells with regard to cytotoxicity, it may be possible to increase cytotoxicity by activation with cytokine combinations like IL-2/IL-15 or by cross-talk with dendritic cells (DCs). Additional investigation is necessary to develop strategies to overcome tumor immune escape mechanisms. Options may encompass development of MAb against sMICA, genetic engineering of NK cells by introduction of chimeric receptors for tumor retargeting, or enhancing tumor cell recognition by using small interfering RNA to silence inhibitory receptors. Open issues in clinical studies also include NK cell dose rate, time schedule, appropriate selection of donor/recipients, and also the types of tumors to be considered for treatment, because it is already known that certain types of malignant cells may be more responsive to NK cell therapy than others. Ultimately, expansion of tumor-reactive NK cells within the patient might prove to be feasible. It is possible to transfuse NK cells simultaneously with the transplants, and the first clinical trials indicate that an early NK application post SCT may be most effective in attacking minimal residual disease.

References


MACS Product Order no.
CliniMACS Plus Instrument 151-01
CliniMACS CD3 Reagent 273-01
CliniMACS CD56 Reagent 271-01
CliniMACS PBS/EDTA Buffer 700-25

The CliniMACS® System components: Reagents, Tubing Sets, Instruments and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked medical devices. In the USA, the CliniMACS System components including the CliniMACS Reagents are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.

Powerful automated cell sorting
From whole blood straight to leukocyte subsets

Time saving
No density gradient centrifugation – with MACS® Whole Blood MicroBeads

Automated
Gentle cell isolation at the push of a button – with the autoMACS® Pro Separator

Reproducible
Easy-to-standardize procedure for multisite studies

Efficient
Parallel isolation of up to 24 samples – with the MultiMACS™ Cell 24 Separator Plus

μ milt en y biotec.com/wholeblood

Available for research use only in the United States.